July 12 (Reuters) - Investment fund Oaktree Capital

Management has raised its stake in Indivior Plc ( INDV ) to

become its second largest shareholder, days after the British

drugmaker issued a profit warning and signalled a slowdown in

sales of its top-selling opioid addiction treatment.

Oaktree, which specialises in providing rescue funding to

struggling firms, disclosed a 6.3% stake in Indivior ( INDV ), a filing

showed on Friday.

Oaktree had a 2.5% stake in the drugmaker, according to LSEG

data. Investment manager Two Seas Capital is the top shareholder

with a nearly 10% ownership.

Indivior ( INDV ), which moved its primary listing to New York last

month, has been facing intense competition in the United States

for its opioid drug Sublocade from the launch of a rival,

Brixadi.

The drugmaker said earlier this week it will discontinue

sales of its schizophrenia drug Perseris, resulting in 130 job

cuts.